Listed

Sono Tek Corp: Form 10-Q for the period ended Aug 31, 2025

Filed with the SEC on Oct 14, 2025 and accepted by EDGAR at Oct 14, 2025, 12:14 ET.

Share

Management's discussion and analysis

As filed, 34,793 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD-LOOKING STATEMENTS

We discuss expectations regarding our future performance, such as our business outlook, in our annual and quarterly reports, news releases, and other written and oral statements. These “forward-looking statements” are based on currently available competitive, financial and economic data and our operating plans. They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, tax, competitive and technological developments affecting our operations or the demand for our products; inflationary and supply chain pressures; the recovery of the Electronics/Microelectronics and Medical markets; rebound of sales to the industrial market in the second quarter of fiscal year 2026; maintenance of increased order backlog; the imposition of tariffs; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions, the ability to enforce patents; maintenance of operating leverage; consummation of order proposals; completion of large orders on schedule and on budget; continued sales growth in the medical and alternative energy markets; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems which are sold at higher average selling prices (“ASP”); and realization of quarterly and annual revenues within the forecasted range of sales guidance.

We undertake no obligation to update any forward-looking statement.

Overview

Founded in 1975, Sono-Tek Corporation is a global leader in designing and manufacturing ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries, including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek’s move into the clean energy sector is showing transformative results in next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture applications as we shape a sustainable future.

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Over the last decade, we have shifted our business from primarily selling ultrasonic nozzles and components to providing complete machine solutions and higher-value subsystems to original equipment manufacturers (OEMs). This strategy has resulted in significant growth of our average unit selling price, with our larger machines often selling for over $300,000 and system prices sometimes reaching over $1,000,000. Consequently, we have broadened our addressable market and believe we can grow sales on a larger scale. We expect that we will experience wide variations in both order flow and shipments from quarter to quarter.

Our comprehensive suite of thin film coating solutions and application consulting services, provided by our expert applications engineers to guide our customers in developing the complete coating process, ensures unparalleled results for our clients and help some of the world’s most promising companies achieve technological breakthroughs and bring them to market. In anticipation of customer demands, our significant focus on R&D efforts allows us to keep pace with industry trends while continuously innovating. We strategically deliver our products through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives located in North America, Latin America, Europe, and Asia, ensuring efficient market reach across diverse sectors around the globe. Approximately 47% of our sales were generated outside the United States and Canada in the first six months of fiscal year 2026.

We continue to expand our sales capabilities by increasing the size of our direct sales force and adding new distributors and sales representatives. In addition, we have established testing labs at our distribution partner sites in China, Taiwan, Germany, Turkey, Korea, and Japan, while also expanding our first testing lab co-located with our manufacturing facilities in New York. These labs provide significant value for demonstrating the capabilities of our equipment to prospective customers and enable us to develop custom solutions to meet their needs.

Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to develop thin-film coating technologies that enable better outcomes for our customers’ products and processes.

Second Quarter Fiscal 2026 Highlights (compared with the second quarter of fiscal 2025 unless otherwise noted) We refer to the three-month periods ended August 31, 2025 and 2024 as the second quarter of fiscal 2026 and fiscal 2025, respectively.

  • Net Sales for the quarter were $5,163,000, up slightly year over year, compared to $5,162,000 for the prior year period.
  • Gross Profit increased 3% or $74,000 to $2,590,000 and the Gross Profit % increased 150 basis points to 50.2% due to a favorable product mix of mature high ASP systems with reduced costs and favorable warranty expenses in the current period.
  • Operating income increased significantly by 47% or $135,000, to $421,000 due to the increase in gross profit combined with a decrease in operating expenses.
  • Interest and dividend income remained steady at $82,000 for the second quarter of fiscal year 2026.
  • Combined equipment and service-related backlog on August 31, 2025 remained robust at $11,210,000, 2% below the prior year record. Sequentially, backlog increased 50% from the first quarter of fiscal 2026, reflecting new order momentum from the medical market.

First Half Fiscal 2026 Highlights (compared with the first half of fiscal 2025 unless otherwise noted) We refer to the six-month periods ended August 31, 2025 and 2024 as the first half of fiscal 2026 and fiscal 2025, respectively.

  • Net Sales for the first half of fiscal 2026 increased by 1% or $103,000 to $10,296,000, achieving growth guidance even with a customers requested shipment delay.
  • Gross Profit increased 6% to $5,254,000, and the Gross Profit % increased 220 basis points to 51% primarily due to product mix and favorable warranty expenses in the current period.
  • Operating Income increased 73% or $381,000 to $905,000, underscoring operating leverage from stronger gross profit and a decrease in operating expenses.
  • Interest and dividend income remained steady at $224,000 for the first half of fiscal year 2026.
  • As of August 31, 2025, the Company had no outstanding debt and had cash, cash equivalents and marketable securities totaling $10.6 million.

15

RESULTS OF OPERATIONS

Sales:

Product Sales

Three Months Ended August 31, 2025 2024 Change $% Six Months Ended August 31, 2025 2024 Change $%
Fluxing Systems $165,000 $119,000 46,000 39% $317,000 $253,000 64,000 25%
In-Line Coating Systems 1 1,530,000 2,023,000 (493,000) (24%) 4,584,000 2,770,000 1,814,000 65%
Multi-Axis Coating Systems 2,030,000 1,931,000 99,000 5% 2,707,000 4,595,000 (1,888,000) (41%)
OEM Systems 394,000 205,000 189,000 92% 524,000 537,000 (13,000) (2%)
Spare Parts, Services and Other 1,044,000 884,000 160,000 18% 2,164,000 2,038,000 126,000 6%
TOTAL $5,163,000 $5,162,000 1,000 0% $10,296,000 $10,193,000 103,000 1%

1. During the current reporting period, the Company updated the title of its product category previously referred to as “Integrated Coating Systems” to “In-Line Coating Systems.” This change was made to provide greater clarity in describing this product line of our business. The definition and contents of this category remain unchanged. In-Line Coating Systems include Sono-Tek products that are typically stationary platforms with minimal motion control, and may occasionally incorporate a simple axis of movement such as a rotation fixture. These systems are commonly installed over moving substrates such as conveyors or webs, which may be provided either by Sono-Tek or by the customer. They often employ multiple ultrasonic nozzles to provide uniform coverage over larger areas in continuous production environments. In-Line Coating Systems are unlike our Multi-Axis Coating Systems, which commonly utilize XYZ motion platforms or 6+ axis robotic configurations.

In-Line Coating Systems declined 24% in the second quarter of fiscal 2026 compared to the prior year period, primarily due to a customer-requested shipment delay. Despite this quarterly dip, In-Line Coating Systems posted strong growth of 65% during the first half of fiscal 2026, driven by six high ASP solar coating system shipments totaling $4.4 million. Multi-Axis Coating Systems increased modestly by 5% in the second quarter of fiscal 2026 but decreased 41% in the first half of fiscal 2026 following a particularly strong first half of fiscal 2025 that included significant semiconductor-related orders that did not repeat in the current period. OEM Systems rose 92% in the second quarter of fiscal 2026 on strong OEM fluxer demand and new optics-related OEM wins, though first half of fiscal 2026 results were relatively flat. Fluxing Systems improved 39% in the second quarter of fiscal 2026 and 25% for the first half of fiscal 2026 influenced by strong fluxer sales in Asia.

Market Sales

Three Months Ended August 31, 2025 2024 Change $% Six Months Ended August 31, 2025 2024 Change $%
Electronics/Microelectronics $1,455,000 $1,477,000 (22,000) (1%) $2,399,000 $3,045,000 (646,000) (21%)
Medical 1,004,000 402,000 602,000 150% 1,812,000 1,259,000 553,000 44%
Alternative/Clean Energy 2,433,000 2,498,000 (65,000) (3%) 5,681,000 4,780,000 901,000 19%
Emerging R&D and Other 33,000 30,000 3,000 10% 47,000 41,000 6,000 15%
Industrial 238,000 755,000 (517,000) (68%) 357,000 1,068,000 (711,000) (67%)
TOTAL $5,163,000 $5,162,000 1,000 0% $10,296,000 $10,193,000 103,000 1%

Medical sales surged 150% in the second quarter of fiscal 2026, led by balloon coating system shipments across the U.S., Europe, and China, with growth of 44% in the first half of fiscal 2026, including both balloon and stent coating systems. Industrial sales declined 68% in the second quarter of fiscal 2026 and 67% in the first half of fiscal 2026, influenced by a large float glass coating order in the first half of fiscal 2025 that did not repeat. Alternative Energy sales were essentially flat in the second quarter of fiscal 2026, though up 19% for the first half of fiscal 2026 on strong solar system shipments. Electronics sales remained relatively steady in the second quarter of fiscal 2026 but declined 21% for the first half of fiscal 2026 due to lower semiconductor demand compared to last year’s elevated levels.

Geographic Sales

Three Months Ended August 31, 2025 2024 Change $% Six Months Ended August 31, 2025 2024 Change $%
U.S. & Canada $2,720,000 $3,495,000 (775,000) (22%) $6,263,000 $6,587,000 (324,000) (5%)
Asia Pacific (APAC) 930,000 368,000 562,000 153% 1,527,000 880,000 647,000 74%
Europe, Middle East, Asia (EMEA) 1,424,000 1,136,000 288,000 25% 2,321,000 2,381,000 (60,000) (3%)
Latin America 89,000 163,000 (74,000) (45%) 185,000 345,000 (160,000) (46%)
TOTAL $5,163,000 $5,162,000 1,000 0% $10,296,000 $10,193,000 103,000 1%

In the first half of fiscal 2026, approximately 39% of sales originated outside of the United States and Canada compared with 35% in the first half of fiscal 2025.

In the second quarter of fiscal 2026, approximately 47% of sales originated outside of the United States and Canada compared with 32% in the second quarter of fiscal 2025.

Asia Pacific sales increased sharply, up 153% in the quarter and 74% year-to-date, led by medical coating device demand in China and alternative energy orders in Japan and South Korea. U.S. and Canada sales declined 22% in the second quarter of fiscal 2026 and 5% for the first half of fiscal 2026, reflecting weaker green energy demand from the US compared to prior year periods. Latin America declined 45% in the second quarter of fiscal 2026 and 46% in the first half of fiscal 2026, reflecting slow activity of PCB fluxing systems in Mexico.

Gross Profit:

Three Months Ended August 31, 2025 2024 Change $% Six Months Ended August 31, 2025 2024 Change $%
Net Sales $5,163,000 $5,162,000 1,000 0% $10,296,000 $10,193,000 103,000 1%
Cost of Goods Sold 2,573,000 2,646,000 (73,000) (3%) 5,042,000 5,222,000 (180,000) (3%)
Gross Profit $2,590,000 $2,516,000 74,000 3% $5,254,000 $4,971,000 283,000 6%
Gross Profit % 50.2% 48.7% 51.0% 48.8%

For the second quarter of fiscal 2026, gross profit increased by $74,000, or 3%, compared with the prior year period. The gross profit percentage was 50.2% compared with 48.7% for the prior year period. The increase in the gross profit percentage was influenced by product mix and favorable warranty expenses in the period.

For the first half of fiscal 2026, gross profit increased by $283,000, or 6%, to $5,254,000 compared with $4,971,000 in the first half of fiscal 2025. The gross profit percentage was 51.0% compared with 48.8% for the prior year period. The increase in the gross profit percentage was influenced by product mix and favorable warranty expenses in the period. This included significant sales of In-Line Coating Systems tied to repeat high ASP orders that shipped to a U.S. based customer, where sales typically involve minimal distributor discounts supporting stronger margins.

Operating Expenses:

Three Months Ended August 31, 2025 2024 Change $% Six Months Ended August 31, 2025 2024 Change $%
Research and product development $627,000 $696,000 (69,000) (10%) $1,296,000 $1,427,000 (131,000) (9%)
Marketing and selling 871,000 988,000 (117,000) (12%) 1,730,000 1,886,000 (156,000) (8%)
General and administrative 670,000 546,000 124,000 23% 1,324,000 1,133,000 191,000 17%
Total Operating Expenses $2,168,000 $2,230,000 (62,000) (3%) $4,350,000 $4,446,000 (96,000) (2%)

17

Research and Product Development:

Research and product development costs decreased in both the second quarter and the first half of fiscal 2026 due to a decrease in salary expense associated with the departure of a senior engineer, research and development materials, supplies and insurance expense. These decreases were partially offset by additional lab salaries.

Marketing and Selling:

Marketing and selling expenses decreased in both the second quarter and the first half of fiscal 2026 due to a decrease in salary expense related to the departure of a salesperson and a decrease in trade show expenses and travel and entertainment expenses. These decreases were partially offset by an increase in salaries related to our sales application lab. Our sales and marketing costs are variable, and a large portion of the costs are dependent upon trade shows and where geographically our sales are generated. We anticipate that our costs will increase in the future as we increase our trade show presence and the potential change in geographic origin of our sales from our in-house sales team to our external distributors.

In the second quarter and first half of fiscal 2026, commission expense decreased approximately $36,000 and $79,000, respectively. The decline was driven by a higher mix of sales closed directly by our in-house team. Our in-house team earns a consistent commission percentage on all sales; when sales are made through distributors or manufacturer representatives, we also incur their additional commissions (and related channel costs), which increases total selling costs. The shift toward direct sales reduced those third-party costs in the current period.

General and Administrative:

General and administrative expenses increased in both the second quarter and first half of fiscal 2026 due to increases in salaries, corporate investor coverage, corporate expenses and stock-based compensation. These increases were partially offset by decreases in legal and accounting fees.

Operating Income:

In the second quarter of fiscal 2026, operating income increased $135,000, or 47%, to $421,000 compared with $286,000 for the second quarter of fiscal 2025. Operating margin for the quarter increased to 8% compared with 6% in the prior year period. In the second quarter of fiscal 2026, an increase in gross profit, combined with a decrease in operating expenses were key factors in the increase of operating income.

In the first half of fiscal 2026, operating income increased $381,000, to $905,000, compared with $524,000 for the first half of fiscal 2025. Operating margin for the first half of fiscal 2026 increased to 9% compared with 5% in the prior year period. In the first half of fiscal 2026, an increase in gross profit, combined with a decrease in operating expenses were key factors in the increase of operating income.

Interest, Dividend Income and Unrealized Gain:

Interest and dividend income remained steady at $82,000 in the second quarter of fiscal 2026 as compared with $85,000 for the second quarter of fiscal 2025. In the first half of fiscal 2026 interest and dividend income decreased by $4,000 to $224,000 as compared with $228,000 for the first half of fiscal 2025. Our present investment policy is to invest excess cash in highly liquid, lower risk US Treasury securities. At August 31, 2025, the majority of our holdings are rated at or above investment grade.

Net unrealized gain decreased $21,000 to $23,000 in the second quarter of fiscal 2026 as compared to $44,000 in the second quarter of fiscal 2025. In the first half of fiscal 2026, unrealized gain decreased $52,000 to $2,000 as compared with $54,000 in the first half of fiscal 2026.

Income Tax Expense:

We recorded income tax expense of $103,000 for the second quarter of fiscal 2026 compared with $74,000 for the second quarter of fiscal 2025. For the first half of fiscal 2026, we recorded income tax expense of $221,000 compared with $134,000 for the first half of fiscal 2025.

The increase in income tax expense in the second quarter fiscal 2026 is due to the increase in income before income taxes combined with an increase in permanent timing differences. These increases were partially offset by the reduction of income taxes due to the application of available research and development tax credits from this quarter’s research and development expenditures.

The deferred tax asset decreased approximately $158,000, to $1,367,000 at August 31, 2025 from $1,525,000 at February 28, 2025. Additionally, the deferred tax liability decreased approximately $44,000, to $88,000 at August 31, 2025 from $132,000 at February 28, 2025. The net decrease in the deferred tax asset and liability was approximately $202,000 for the first half of fiscal 2026. This decrease is primarily due to the retroactive expensing of research and development expenses that were capitalized for tax purposes, prior to the enactment of the One Big Beautiful Bill Act (the “Act” or “OBBBA”) on July 4. 2025.

The Act introduces significant changes to the Internal Revenue Code, including the permanent extension of many provisions of the 2017 Tax Cuts and Jobs Act (“TCJA”) and various new tax incentives and adjustments. The financial reporting implications of the Act were recorded in the income tax provision for the quarter and year to date periods ended August 31, 2025, in accordance with ASC 740, Income Taxes.

The OBBBA did not change the statutory U.S. federal tax rate. Accordingly, the OBBBA did not compel us to remeasure our deferred tax assets and liabilities solely because of a rate change. However, the various changes in tax law did impact our current and deferred tax calculations.

The most significant tax provisions impacting us include:

Bonus Depreciation – The Act permanently restores 100% bonus depreciation for qualified property acquired and placed into service after January 19, 2025. This change will likely lead to a reduction in current tax payable for capital expenditures in fiscal year 2026.

Research and Development (“R&D) Costs – The Act reinstates the ability for entities to immediately expense domestic R&D costs for tax years beginning after December 31, 2024. Certain small businesses may also retroactively expense R&D costs, which were capitalized under the TCJA during the calendar years 2022 – 2024. The retroactive expensing of these R&D costs may generate tax refunds.

Net Income:

Net income increased by $83,000 to $424,000 for the second quarter of fiscal 2026 compared with $341,000 for the second quarter of fiscal 2025. The increase in net income during the second quarter is primarily a result of an increase in gross profit combined with a decrease in operating expenses, partially offset by an increase in income tax expense.

Net income increased by $237,000 to $909,000 for the first half of fiscal 2026 compared with $672,000 for the first half of fiscal 2025. The increase in net income during the first half of fiscal 2026 is primarily a result of an increase in gross profit combined with a decrease in operating expenses, partially offset by an increase in income tax expense.

Liquidity and Capital Resources

Working Capital – Our working capital increased $1,219,000 to $14,720,000 at August 31, 2025 from $13,501,000 at February 28, 2025. The increase in working capital was mostly the result of the current period’s net income and noncash charges partially offset by purchases of equipment.

We aggregate cash and cash equivalents and marketable securities in managing our balance sheet and liquidity. For purposes of the following analysis, the total is referred to as “Cash.” At August 31, 2025 and February 28, 2025, our working capital included:

August 31, 2025 February 28, 2025 Cash Increased (Decrease)
Cash and cash equivalents $3,832,000 $5,202,000 $(1,370,000)
Marketable securities 6,736,000 6,728,000 8,000
Total $10,568,000 $11,930,000 $(1,362,000)

The following table summarizes the accounts and the major reasons for the $1,362,000 decrease in “Cash”:

Impact on Cash Reason
Net income, adjusted for non-cash items $1,550,000 To reconcile increase in cash.
Accounts receivable increase (1,865,000) Timing of cash receipts.
Inventories decrease 255,000 Decrease in inventory due to completed sales.
Customer deposits decrease (506,000) Decrease due to completed sales.
Accounts payable decrease (245,000) Timing of disbursements.
Accrued expenses increase 134,000 Timing of disbursements.
Prepaid and Other Assets decrease 47,000 Decrease in prepaid expenses.
Income tax payable decrease (468,000) Timing of disbursements.
Equipment purchases (113,000) Equipment and facilities upgrade.
Treasury stock purchases (151,000) Purchase of treasury stock.
Net decrease in cash $(1,362,000)

Stockholders’ Equity – Stockholders’ Equity increased $904,000 from $17,792,000 at February 28, 2025 to $18,696,000 at August 31, 2025. The increase is a result of the current period’s net income of $909,000 and $146,000 in additional equity related to stock-based compensation awards. These increases were partially offset by treasury stock purchases of $151,000. The details of stock-based compensation awards are explained in Note 5 in our financial statements.

Operating Activities – We used $1,099,000 of cash in our operating activities in the first half of fiscal 2026 compared to using $90,000 of cash in the first half fiscal 2025, an increase of $1,009,000. The increase in cash used in our operating activities was the result of an increase in accounts receivable combined with decreases in accounts payable, income taxes payable and customer deposit balances.

During the past year, we have experienced a shift in customer mix toward larger, more financially stable companies that generally operate under stricter standard payment terms. As a result, customer deposits decreased and accounts receivable increased, reflecting a normalization of payment practices relative to prior years when we secured high upfront deposits.

In the first half of fiscal year 2026, our accounts receivable increased $1,865,000 when compared to the prior year period. The increase in accounts receivable is primarily due to revised payment terms provided to one customer that purchased six units during the first half of fiscal year 2026, with a total sales price of $4.4 million. After completion of the first quarter of fiscal year 2026, the customer requested a modification to the timing of one of their scheduled payments due to a shift in their production plans from overseas to the United States. Because we have already collected a significant cash down payment on the order and we anticipate only a modest delay of approximately two months on a portion of the next payment, we accommodated the customer’s request. The customer has indicated that they will return to the originally agreed payment schedule thereafter. Based on our long-standing relationship and ongoing communications, we do not currently foresee any collection issues with this customer.

In the first half of fiscal year 2026, our inventories decreased $255,000 when compared to the prior year. The decrease in inventories is due to the completion of customer orders in the second half of fiscal 2026.

In the second half of fiscal year 2026, our income taxes payable decreased $252,000 when compared to the prior year. The decrease in income taxes payable is due to cash payments on our current year tax returns and required estimated payments.

Investing Activities – For the first half of fiscal year 2026, our investing activities used $120,000 of cash compared with providing $3,808,000 for the first half of fiscal 2025. For the first half of fiscal years 2026 and 2025, we used $113,000 and $191,000, respectively, for the purchase or manufacture of equipment, furnishings and leasehold improvements.

In the first half of fiscal year 2026, net purchases of marketable securities used $8,000 of cash compared with providing $3,999,000 from the net sales of marketable securities in the prior year period.

Financing Activities – In the first half of fiscal year 2026, we used $151,000 of cash for the purchase of treasury stock.

Net Decrease in Cash and Cash Equivalents – In the first half of fiscal 2026, our cash balance decreased by $1,370,000 as compared to an increase of $3,718,000 in the first half of fiscal 2025. In the first half of fiscal 2026, our operating activities used $1,099,000 of cash and purchases of our marketable securities used $8,000. In addition, we used $113,000 for the purchase or manufacture of equipment, furnishings and leasehold improvements and we used $151,000 for the purchase of treasury stock.

Critical Accounting Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure on contingent assets and liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions and conditions.

Management’s estimates and judgments are continually evaluated and are based on historical experience and expectations regarding future events that are believed to be reasonable under the specific circumstances.

Critical accounting estimates are defined as those that are reflective of significant judgments and uncertainties and may potentially result in materially different results under different assumptions and conditions. The Company believes that critical accounting policies are limited to those described below. For a detailed discussion on the application of these and other accounting policies see Note 2 to the Company’s consolidated financial statements included in Form 10-K for the year ended February 28, 2025.

Accounting for Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized. We use a recognition threshold and a measurement attribute for financial statement recognition and measurement tax positions taken or expected to be taken in a return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. As of August 31, 2025 and August 31, 2024, there were no uncertain tax provisions.

On July 4, 2025, the One Big Beautiful Bill Act (the “Act” or “OBBBA”) was signed into law. The Act introduces significant changes to the Internal Revenue Code, including the permanent extension of many provisions of the 2017 Tax Cuts and Jobs Act (“TCJA”) and various new tax incentives and adjustments. The financial reporting implications of the Act were recorded in the income tax provision for the quarter and year to date periods ended August 31, 2025, in accordance with ASC 740, Income Taxes.

The OBBBA did not change the statutory U.S. federal tax rate. Accordingly, the OBBBA did not compel the Company to remeasure its deferred tax assets and liabilities solely because of a rate change. However, the various changes in tax law did impact the Company’s current and deferred tax calculations.

The most significant tax provisions impacting the Company include:

Bonus Depreciation – The Act permanently restores 100% bonus depreciation for qualified property acquired and placed into service after January 19, 2025. This change will likely lead to a reduction in current tax payable for capital expenditures in fiscal year 2026.

Research and Development (“R&D) Costs – The Act reinstates the ability for entities to immediately expense domestic R&D costs for tax years beginning after December 31, 2024. Certain small businesses may also retroactively expense R&D costs, which were capitalized under the TCJA during the calendar years 2022 – 2024. The retroactive expensing of these R&D costs may generate tax refunds.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services.

Judgment is required when determining at what point in time control of the Company’s manufactured equipment is transferred to its customers. Management’s judgment is based on each customer contract and the transfer of control of the equipment to the customer. The sales revenue to be recorded is based on each contract.

Impact of New Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.

Other than ASU 2023-09 and ASU 2024-03 discussed above, accounting pronouncements issued but not yet effective have been deemed to be not applicable or the adoption of such accounting pronouncements is not expected to have a material impact on the financial statements of the Company.

Market risk

As filed, 537 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company does not issue or invest in financial instruments or derivatives for trading or speculative purposes. Substantially all of the operations of the Company are conducted in the United States, and, as such, are not subject to material foreign currency exchange rate risk. All of our sales transactions are completed in US dollars.

Although the Company's assets included $3,832,000 in cash and $6,736,000 in marketable securities, the market rate risk associated with changing interest rates in the United States is not material.

Controls and procedures

As filed, 1,286 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company has established and maintains “disclosure controls and procedures” (as those terms are defined in Rules 13a –15(e) and 15d-15(e) under the Securities and Exchange Act of 1934 (the “Exchange Act”). R. Stephen Harshbarger, Chief Executive Officer (principal executive) and Stephen J. Bagley, Chief Financial Officer (principal accounting officer) of the Company, have evaluated the Company’s disclosure controls and procedures as of August 31, 2025. Based on this evaluation, they have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) accumulated and communicated to Management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding timely disclosure.

In addition, there were no changes in the Company’s internal controls over financial reporting during the second fiscal quarter of fiscal year 2026 that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

Risk factors

As filed, 150 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There are no material changes from risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the year ended February 28, 2025.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-08-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-06-01 to 2025-08-31$5.2mus-gaap:Revenues
Revenue6 months2025-03-01 to 2025-08-31$10.3mus-gaap:Revenues
Cost of revenue3 months2025-06-01 to 2025-08-31$2.6mus-gaap:CostOfRevenue
Cost of revenue6 months2025-03-01 to 2025-08-31$5.0mus-gaap:CostOfRevenue
Gross profit3 months2025-06-01 to 2025-08-31$2.6mus-gaap:GrossProfit
Gross profit6 months2025-03-01 to 2025-08-31$5.3mus-gaap:GrossProfit
Research and development3 months2025-06-01 to 2025-08-31$627.3kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2025-03-01 to 2025-08-31$1.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-06-01 to 2025-08-31$421.2kus-gaap:OperatingIncomeLoss
Operating income6 months2025-03-01 to 2025-08-31$904.5kus-gaap:OperatingIncomeLoss
Income tax3 months2025-06-01 to 2025-08-31$102.5kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-03-01 to 2025-08-31$221.1kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-06-01 to 2025-08-31$423.7kus-gaap:NetIncomeLoss
Net income6 months2025-03-01 to 2025-08-31$908.7kus-gaap:NetIncomeLoss
Diluted EPS3 months2025-06-01 to 2025-08-31$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-03-01 to 2025-08-31$0.06us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-06-01 to 2025-08-31$0.03us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-03-01 to 2025-08-31$0.06us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-06-01 to 2025-08-3115,731,571 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-03-01 to 2025-08-3115,740,384 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-03-01 to 2025-08-31−$1.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2025-03-01 to 2025-08-31$112.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-08-31$3.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-08-31$19.1mus-gaap:AssetsCurrent
Total assetsAt period end2025-08-31$23.2mus-gaap:Assets
Current liabilitiesAt period end2025-08-31$4.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-08-31$4.5mus-gaap:Liabilities
Shareholders' equityAt period end2025-08-31$18.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171520-25-000319. Last ingested by Listed: Oct 24, 2026, 14:57 ET. Listed shows no prices and gives no investment advice.